Edwards Lifesciences (EW) Total Non-Current Liabilities (2009 - 2026)

Edwards Lifesciences' Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $2.6 billion for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 6.87% year-over-year to $2.6 billion in Q1 2026; TTM through Mar 2026 was $2.6 billion, a 6.87% increase from a year earlier, with the FY2025 full-year figure at $3.0 billion, up 14.44% from the prior year.
• Total Non-Current Liabilities retreated to $2.6 billion in Q1 2026 per EW's latest filing, from $3.0 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $3.0 billion in Q3 2024 and bottomed at $2.2 billion in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $2.4 billion (2023), against an average of $2.5 billion.
• Across the five-year window, Total Non-Current Liabilities plunged 70.48% in 2022 and climbed 25.41% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $2.3 billion in 2022, then climbed by 5.48% to $2.4 billion in 2023, then climbed by 9.47% to $2.6 billion in 2024, then gained by 14.44% to $3.0 billion in 2025, then retreated by 11.82% to $2.6 billion in 2026.
• Per Business Quant, the three latest EW Total Non-Current Liabilities figures stand at $2.6 billion (Q1 2026), $3.0 billion (Q4 2025), and $2.7 billion (Q3 2025).